Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, People's Republic of China.
State Key Laboratory of Oncology in South China, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, People's Republic of China.
Cancer Immunol Immunother. 2023 Dec;72(12):4209-4219. doi: 10.1007/s00262-023-03557-6. Epub 2023 Oct 14.
To assess the antitumor activity of neoadjuvant chemotherapy in conjunction with PD-1 inhibitors (neoadjuvant chemoimmunotherapy) among patients with oropharyngeal and hypopharyngeal squamous cell carcinoma (OPHSCC) and compare its efficacy with neoadjuvant chemotherapy alone.
We conducted a retrospective analysis using data from patients diagnosed with OPHSCC and treated at the Sun Yat-sen University Cancer Center between September 2012 and August 2022. We included patients who received neoadjuvant chemotherapy alone or combined with PD-1 inhibitors. We assessed the clinical response using the Response Evaluation Criteria in Solid Tumors and evaluated progression-free survival (PFS) and overall survival (OS).
Preliminary results demonstrate that neoadjuvant chemoimmunotherapy exhibited robust antitumor activity in OPHSCC, with an impressive overall response rate (ORR) of 81.0%. Complete response and partial response rates were 14.9% and 65.9%, respectively. Notably, neoadjuvant chemoimmunotherapy demonstrated superior PFS and OS to neoadjuvant chemotherapy alone. The 1-year PFS rate was 80.7%, and the 2-year rate was 61.1%. Additionally, the 1-year OS rate reached 92.3%. Finally, a multivariate analysis identified the American Joint Committee on Cancer stage reduction post-treatment as a favorable predictor of PFS.
Our results underscore the promising potential of neoadjuvant chemoimmunotherapy in enhancing antitumor activity in patients with OPHSCC. The robust ORR, along with improved PFS and OS, supports the utility of this combined approach. These results pave the way for further investigations to validate and refine the application of neoadjuvant chemoimmunotherapy in this challenging clinical context.
评估新辅助化疗联合 PD-1 抑制剂（新辅助化疗免疫治疗）在口咽和下咽鳞状细胞癌（OPHSCC）患者中的抗肿瘤活性，并将其与单纯新辅助化疗的疗效进行比较。
我们使用 2012 年 9 月至 2022 年 8 月中山大学肿瘤防治中心诊断为 OPHSCC 并接受治疗的患者数据进行了回顾性分析。纳入接受单纯新辅助化疗或联合 PD-1 抑制剂治疗的患者。我们使用实体瘤反应评价标准评估临床反应，并评估无进展生存期（PFS）和总生存期（OS）。
初步结果表明，新辅助化疗免疫治疗在 OPHSCC 中具有强大的抗肿瘤活性，总缓解率（ORR）令人印象深刻，为 81.0%。完全缓解和部分缓解率分别为 14.9%和 65.9%。值得注意的是，新辅助化疗免疫治疗在 PFS 和 OS 方面优于单纯新辅助化疗。1 年 PFS 率为 80.7%，2 年率为 61.1%。此外，1 年 OS 率达到 92.3%。最后，多变量分析确定治疗后美国癌症联合委员会分期降低是 PFS 的有利预测因素。
我们的结果强调了新辅助化疗免疫治疗在增强 OPHSCC 患者抗肿瘤活性方面的有前途的潜力。强大的 ORR，以及改善的 PFS 和 OS，支持这种联合方法的应用。这些结果为进一步研究验证和完善新辅助化疗免疫治疗在这一具有挑战性的临床环境中的应用铺平了道路。
